Related Experiment Video
Updated: Jan 3, 2026
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Real world data of combined lung cancer and interstitial lung disease
Tatsuo Kawahara1, Hiroyuki Sakashita1,2, Takafumi Suzuki1
1Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Background:
Research patients with combined lung cancer (LC) and interstitial lung disease (ILD) is insufficient. The objective of the study was to identify the frequency of such patients and treatments, including best supportive care (BSC), in the real world.
Methods:
All patients with LC who were admitted to our hospital over a 5-year period from 2013 to 2017 were retrospectively analysed.
Results:
In this study, 698 patients with LC were enrolled. A total of 148 (21.2%) suffered from LC and ILD. Seventy-one LC-ILD patients received chemotherapy, and 20 LC-ILD patients received BSC only. Eleven BSC patients whom physicians thought could receive therapy declined treatment. The median survival time of patients who received chemotherapy was 14.3 months (95% confidence interval, 8.5-19.4 months). The median survival time of BSC patients who declined treatment was 7.2 months and that was shorter than that of patients who received chemotherapy.
Conclusions:
This study suggests that patients with combined LC and ILD are common (21.2%) in the real world, and there is the possibility that therapy for LC-ILD patients is beneficial.
Related Concept Videos
01:25Statistical Methods for Analyzing Epidemiological Data
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...